^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ER (Estrogen receptor)

    i
    Other names: ESR1, Era, ESR, NR3A1, ER, ER beta
    18h
    SUMIT-ELA: A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=49, Completed, Carrick Therapeutics Limited | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • CDK4 (Cyclin-dependent kinase 4)
    |
    TP53 mutation • ER positive • HER-2 negative • ESR1 mutation • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation
    |
    Orserdu (elacestrant) • samuraciclib (CT7001)
    1d
    Identification, synthesis, and characterization of a unique N-glucuronide of an acid metabolite of camizestrant (AZD9833) in humans. (PubMed, Drug Metab Dispos)
    SIGNIFICANCE STATEMENT: Metabolite M14 of camizestrant (AZD9833), a major circulating metabolite in humans, was successfully identified as an N-glucuronide of an acid metabolite of camizestrant, and its unusual chromatographic and stability properties were characterized. The development of a novel hybrid chemical and biological synthesis for M14 has introduced a new approach to synthesizing glucuronides of compounds with acidic functional groups that otherwise interfere with their own in vitro glucuronidation.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive
    |
    camizestrant (AZD9833)
    3d
    CHANCES: A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=27, Recruiting, Institut Paoli-Calmettes | Trial completion date: Feb 2026 --> Mar 2027 | Trial primary completion date: Mar 2025 --> Mar 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset)
    |
    PD-L1 expression • HER-2 positive • HER-2 amplification • HER-2 expression • BRCA mutation • PD-L1 expression + HER-2 overexpression
    |
    Herceptin (trastuzumab) • paclitaxel • IPH5301
    3d
    PLANET: Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy (clinicaltrials.gov)
    P3, N=1000, Not yet recruiting, The Netherlands Cancer Institute
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 expression
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • capecitabine
    3d
    LESLIE: LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=356, Recruiting, Universitaire Ziekenhuizen KU Leuven | Not yet recruiting --> Recruiting | Trial completion date: Mar 2031 --> Sep 2031 | Trial primary completion date: Mar 2028 --> Sep 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • cyclophosphamide • epirubicin
    4d
    A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer (clinicaltrials.gov)
    P2/3, N=706, Recruiting, Shanghai Henlius Biotech | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive
    |
    docetaxel • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • HLX22
    4d
    A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer (clinicaltrials.gov)
    P2, N=176, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    tamoxifen
    4d
    CRYSTAL: Cryoablation Versus Lumpectomy in Early-Stage Breast Cancer (clinicaltrials.gov)
    P3, N=938, Not yet recruiting, Franciscus Gasthuis & Vlietland (Hospital)
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    4d
    Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial. (PubMed, JAMA Oncol)
    The final analysis of the BRIGHT-2 randomized clinical trial confirms improved PFS with the addition of bireociclib to fulvestrant, with manageable safety as a treatment option for patients with HR-positive, ERBB2-negative ABC with progression after prior endocrine therapy. ClinicalTrials.gov Identifier: NCT05077449.
    Clinical • P3 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    HR positive • HER-2 negative • EGFR positive
    |
    fulvestrant • Xuan Yue Ning (bireociclib)
    4d
    A Comparative Analysis of the Utility of Nottingham Prognostic Index and Ki-67 in Selecting ER-positive HER2-negative Patients for Oncotype DX Testing. (PubMed, Clin Breast Cancer)
    NPI, using a threshold of 3.4 as recommended by NICE, may assist in identifying patients for whom Oncotype DX testing could be considered. Ki-67 may provide additional prognostic context when interpreted alongside NPI. These markers may contribute to broader risk stratification frameworks but should be viewed as complementary to genomic testing.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    Oncotype DX Breast Recurrence Score®Test
    4d
    Patient-derived xenograft models of primary breast cancer for preclinical evaluation of neoadjuvant therapies. (PubMed, Sci Transl Med)
    For triple-negative IBC, we demonstrated that neoadjuvant treatment does not benefit from addition of a PARP inhibitor, whereas for estrogen receptor-positive IBC, the combination of a CDK4/6 inhibitor and fulvestrant improved neoadjuvant treatment response. Our work provides a valuable resource of primary IBC models to study breast cancer biology and develop neoadjuvant treatments.
    Preclinical • Journal
    |
    ER (Estrogen receptor)
    |
    ER positive
    |
    fulvestrant • Undisclosed CDK4/6 inhibitor
    4d
    Statin use and risk of contralateral breast cancer: an updated cohort study with landmark analysis. (PubMed, Eur J Epidemiol)
    Stratification by oestrogen receptor status and pre-diagnosis statin use had no substantial influence on the associations. In conclusion, our study did not support an inverse association between statin use and CBC incidence following a breast cancer diagnosis.
    Journal
    |
    ER (Estrogen receptor)